MCID: PNC013
MIFTS: 43

Pancreatic Ductal Carcinoma

Categories: Cancer diseases, Endocrine diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Pancreatic Ductal Carcinoma

MalaCards integrated aliases for Pancreatic Ductal Carcinoma:

Name: Pancreatic Ductal Carcinoma 11 14
Carcinoma, Pancreatic Ductal 43 71
Malignant Neoplasm of Duct of Wirsung 11
Carcinoma Pancreatic Ductal 53
Pancreatic Duct Cancer 11

Classifications:



External Ids:

Disease Ontology 11 DOID:3587
ICD9CM 34 157.3
MeSH 43 D021441
SNOMED-CT 68 93939009
ICD10 31 C25.3
UMLS 71 C0153461 C0887833

Summaries for Pancreatic Ductal Carcinoma

Disease Ontology: 11 A pancreatic carcinoma located in the pancreatic duct.

MalaCards based summary: Pancreatic Ductal Carcinoma, also known as carcinoma, pancreatic ductal, is related to pancreatic ductal adenocarcinoma and pancreatic adenocarcinoma. An important gene associated with Pancreatic Ductal Carcinoma is SMAD4 (SMAD Family Member 4), and among its related pathways/superpathways are Disease and ERK Signaling. The drugs Axitinib and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include pancreatic duct, pancreas and myeloid, and related phenotypes are Reduced mammosphere formation and nervous system

Related Diseases for Pancreatic Ductal Carcinoma

Diseases related to Pancreatic Ductal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 397)
# Related Disease Score Top Affiliating Genes
1 pancreatic ductal adenocarcinoma 31.1 SMAD4 MIR10B KRAS HRAS CCR6
2 pancreatic adenocarcinoma 30.8 VEGFA TYMP SMAD4 KRAS HRAS CDKN2A
3 neuroendocrine tumor 30.5 VEGFA KRT20 GRP CHGA
4 pancreatic cystadenocarcinoma 30.5 MUC6 KRAS
5 microcystic adenoma 30.5 MUC6 MUC1 CHGA
6 benign mesothelioma 30.5 KRT7 KRT20 CDKN2A
7 acinar cell carcinoma 30.5 SMAD4 KRT7 CHGA
8 tubular adenocarcinoma 30.3 MUC6 MUC5AC MUC2 MUC1 KRT7 KRT20
9 mucoepidermoid carcinoma 30.3 MUC5AC MUC2 MUC1 KRT8 KRT7
10 adenocarcinoma 30.2 VEGFA TYMP SMAD4 MUC5AC MUC1 KRT7
11 cystadenoma 30.2 MUC6 MUC5AC MUC1 KRT7 KRT20 CHGA
12 cystadenocarcinoma 30.1 VEGFA MUC5AC MUC2 MUC1 KRT7 KRAS
13 breast ductal carcinoma 30.1 SMAD4 MUC5AC MUC1 KRT8 KRT7 CHGA
14 ovarian serous cystadenocarcinoma 30.1 SMAD4 MUC1 KRAS HRAS CDKN2A
15 serous cystadenocarcinoma 30.1 TYMP KRT7 KRAS HRAS CDKN2A
16 suppression of tumorigenicity 12 30.0 VEGFA SMAD4 KRT8 HRAS CHGA CDKN2A
17 appendix adenocarcinoma 30.0 SMAD4 KRT7 KRT20 KRAS HRAS CHGA
18 squamous cell carcinoma 29.9 VEGFA SMAD4 MUC1 KRT7 KRAS HRAS
19 adenoma 29.9 SMAD4 MUC6 MUC5AC MUC1 KRT7 KRT20
20 colon adenocarcinoma 29.8 VEGFA SMAD4 KRT20 KRAS HRAS GRP
21 colonic benign neoplasm 29.7 VEGFA SMAD4 MUC5AC KRT7 KRT20 KRAS
22 lung cancer susceptibility 3 29.5 VEGFA TYMP SMAD4 MUC5AC MUC1 KRT8
23 pancreatic cancer 29.3 VEGFA TYMP TGM2 SMAD4 MUC6 MUC5AC
24 gastric cancer 29.1 VEGFA TYMP SMAD4 MUC6 MUC5AC MUC2
25 ovarian cancer 28.8 VEGFA TYMP TGM2 SMAD4 MUC5AC MUC1
26 colorectal cancer 28.5 VEGFA TYMP SMAD4 MUC6 MUC5AC MUC2
27 pancreatic adenosquamous carcinoma 11.2
28 microphthalmia, syndromic 9 10.6
29 scrotum paget's disease 10.5 MUC1 KRT7
30 intrahepatic biliary papillomatosis 10.5 MUC5AC MUC1
31 bile duct signet ring cell carcinoma 10.5 KRT7 KRT20
32 pancreatic foamy gland adenocarcinoma 10.4 MUC1 KRT7
33 anal gland adenocarcinoma 10.4 MUC5AC KRT7
34 cervical basaloid squamous cell carcinoma 10.4 KRT7 CDKN2A
35 anus adenocarcinoma 10.4 MUC5AC KRT7
36 bile duct mucinous adenocarcinoma 10.4 MUC5AC MUC1
37 urethral villous adenoma 10.4 KRT7 KRT20
38 anal paget's disease 10.4 KRT7 KRT20
39 seminal vesicle adenocarcinoma 10.4 KRT7 KRT20
40 nephrogenic adenoma of urinary bladder 10.4 KRT7 KRT20
41 pancreatic serous cystadenocarcinoma 10.4 KRT7 KRT20
42 inverted transitional papilloma 10.4 KRT7 CDKN2A
43 mucinous bronchioloalveolar adenocarcinoma 10.4 KRT7 KRT20
44 bladder benign neoplasm 10.4 KRT7 KRT20
45 anal canal paget's disease 10.4 KRT7 CDKN2A
46 lacrimal gland mucoepidermoid carcinoma 10.4 KRT7 KRT20
47 vulva adenocarcinoma 10.4 KRT7 KRT20
48 aortic malignant tumor 10.4 KRT7 KRT20
49 endometrial squamous cell carcinoma 10.4 KRT7 CDKN2A
50 subareolar duct papillomatosis 10.4 KRT8 KRT7

Graphical network of the top 20 diseases related to Pancreatic Ductal Carcinoma:



Diseases related to Pancreatic Ductal Carcinoma

Symptoms & Phenotypes for Pancreatic Ductal Carcinoma

GenomeRNAi Phenotypes related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 CCR6 CHGA FASLG HRAS KRAS KRT7

MGI Mouse Phenotypes related to Pancreatic Ductal Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.15 CCR6 CDKN2A CHGA FASLG GRP HRAS
2 homeostasis/metabolism MP:0005376 10.13 CCR6 CDKN2A CHGA FASLG HRAS KRAS
3 neoplasm MP:0002006 10.09 CDKN2A FASLG HRAS KRAS MUC1 MUC2
4 no phenotypic analysis MP:0003012 10.01 CDKN2A CHGA HRAS KRAS MIR10B MUC1
5 renal/urinary system MP:0005367 9.92 CHGA FASLG HRAS KRAS KRT7 SMAD4
6 endocrine/exocrine gland MP:0005379 9.85 CDKN2A CHGA FASLG HRAS KRAS MUC1
7 digestive/alimentary MP:0005381 9.65 CDKN2A FASLG HRAS KRAS KRT8 MUC1
8 cardiovascular system MP:0005385 9.4 CCR6 CDKN2A CHGA FASLG GRP HRAS

Drugs & Therapeutics for Pancreatic Ductal Carcinoma

Drugs for Pancreatic Ductal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 58)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Axitinib Approved, Investigational Phase 3 319460-85-0 6450551
2
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
3
Gemcitabine Approved Phase 3 95058-81-4, 122111-03-9 60750
4
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741
5 Protein Kinase Inhibitors Phase 3
6 Antiviral Agents Phase 3
7 Albumin-Bound Paclitaxel Phase 3
8 Anti-Infective Agents Phase 3
9 Antimitotic Agents Phase 3
10 Antimetabolites Phase 3
11 Tubulin Modulators Phase 3
12 Immunosuppressive Agents Phase 3
13 Immunologic Factors Phase 3
14
Erlotinib Approved, Investigational Phase 2 183319-69-9, 183321-74-6 176870
15
Pancrelipase Approved, Investigational Phase 1, Phase 2 53608-75-6 8519
16
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
17
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
18
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
19
Apaziquone Investigational Phase 1, Phase 2 114560-48-4 5813717
20 Pancreatin Phase 1, Phase 2
21 Liposomal doxorubicin Phase 2
22 topoisomerase I inhibitors Phase 2
23 Radiopharmaceuticals Phase 2
24 FAPI-46 Phase 2
25 FOLFIRINOX Phase 2
26
Cisplatin Approved Phase 1 15663-27-1 2767 5702198 441203
27
Carboplatin Approved Phase 1 41575-94-4 10339178 38904
28
Etoposide Approved Phase 1 33419-42-0 36462
29
Durvalumab Approved, Investigational Phase 1 1428935-60-7
30
Tremelimumab Approved, Investigational Phase 1 745013-59-6
31
Azacitidine Approved, Investigational Phase 1 320-67-2 9444
32
Folic acid Approved, Nutraceutical, Vet_approved Phase 1 59-30-3 6037
33 Vitamins Phase 1
34 Folate Phase 1
35
Etoposide phosphate Phase 1 16760419
36 Vitamin B9 Phase 1
37 Trace Elements Phase 1
38 Vitamin B Complex Phase 1
39 Calcium, Dietary Phase 1
40 Antidotes Phase 1
41 Hematinics Phase 1
42 Antineoplastic Agents, Immunological Phase 1
43 Micronutrients Phase 1
44 Protective Agents Phase 1
45 Cc-486 Phase 1
46 Immunoglobulins Phase 1
47 Antibodies Phase 1
48 Mitogens Phase 1
49
Calcium Nutraceutical Phase 1 7440-70-2 271
50
Fluorouracil Approved 51-21-8 3385

Interventional clinical trials:

(show all 39)
# Name Status NCT ID Phase Drugs
1 A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Completed NCT02993731 Phase 3 Napabucasin;Nab-paclitaxel;Gemcitabine
2 A Randomized, Double-Blind Phase 3 Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine Plus Placebo For The First-Line Treatment Of Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer. Completed NCT00471146 Phase 3 AG-013736;Gemcitabine;placebo
3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Subjects With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma Terminated NCT02715804 Phase 3 Placebo;nab-Paclitaxel;Gemcitabine
4 Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer Unknown status NCT02529579 Phase 1, Phase 2 Gemcitabine
5 Phase II Study of Chemotherapy Selection Based on Therapeutic Targets for the Treatment of Advanced Pancreatic Cancer Unknown status NCT01394120 Phase 2 Targeted Therapy Tailored Treatment;Standard Chemotherapy
6 A Non-controlled, Single Arm, Open Label, Phase II Study of Intravenous and Intratumoral Administration of ParvOryx in Patients With Metastatic, Inoperable Pancreatic Cancer Completed NCT02653313 Phase 1, Phase 2 Parvovirus H-1 (H-1PV)
7 A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer Completed NCT00902291 Phase 2
8 An Open-Label Phase 2 Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002 Completed NCT01608711 Phase 2
9 A PHASE Ib/IIa STUDY OF COMBINATION THERAPY WITH GEMCITABINE AND ATU027 IN SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC ADENOCARCINOMA Completed NCT01808638 Phase 1, Phase 2 Atu027 & gemcitabine in lead in safety period;Atu027 & gemcitabine in treatment arm 1;Atu027 & gemcitabine in treatment arm 2
10 A Multicenter, Open-Label Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) in Subjects With Advanced or Unresectable Pancreatic Ductal Carcinoma Whose Tumors Have Progressed Following Prior Treatment With Gemcitabine and Fluoropyrimidine-Based Chemotherapy Completed NCT01580397 Phase 2 INNO-206
11 Ultrasound-enhanced Uptake of Chemotherapy in Patients With Inoperable Pancreatic Ductal Adenocarcinoma - A Randomized Controlled Trial Recruiting NCT04146441 Phase 2 Chemotherapy
12 A Phase II, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of the Combination of S-1, Irinotecan and Oxaliplatin (SIRIOX) in Treating Patients With Advanced Inoperable or Metastatic Pancreatic Cancer Recruiting NCT03403101 Phase 2 S1;Oxaliplatin;Irinotecan
13 A Phase 1/2a Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of JAB-21822 in Combination With JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation Recruiting NCT05288205 Phase 1, Phase 2 JAB-21822;JAB-3312
14 A Phase 2, Multicenter, Single Arm, Open Label Non-Randomized Study of [68Ga]FAPI-46 PET in Patients With Resectable or Borderline Resectable Pancreatic Ductal Carcinoma Recruiting NCT05262855 Phase 2 [68Ga]FAPI-46
15 Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer Terminated NCT02243007 Phase 2 FOLFIRINOX;Gemcitabine/nab-Paclitaxel;Capecitabine
16 A Multicenter Phase II Trial of Weekly Gemcitabine, Paclitaxel, and Hyperfractionated External Irradiation (63.80 GY) for Locally Advanced Pancreatic Cancer Withdrawn NCT00226746 Phase 2 Paclitaxel and gemcitabine
17 A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Patients With Advanced Solid Tumors. Completed NCT02658214 Phase 1 paclitaxel + carboplatin;carboplatin + etoposide;gemcitabine + carboplatin;nab-paclitaxel (paclitaxel-albumin) + carboplatin;oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid);nab-paclitaxel (paclitaxel-albumin) + gemcitabine;cisplatin + 5-fluorouracil (5FU)
18 A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors Completed NCT01478685 Phase 1 CC-486;Carboplatin;ABI-007
19 A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Adult Patients With Advanced Solid Tumors Recruiting NCT04121286 Phase 1 JAB-3312
20 A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Adult Patients With Advanced Solid Tumors Recruiting NCT04045496 Phase 1 JAB-3312
21 A Phase 1/1b Dose Escalation and Cohort Expansion Study of MGC018 in Combination With Checkpoint Inhibitor in Participants With Advanced Solid Tumors Recruiting NCT05293496 Phase 1
22 An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy Unknown status NCT02310230
23 Correlation of Serum CA19-9 Levels With Levels in Saliva and Urine of Patients With Ductal Adenocarcinoma of the Pancreas Unknown status NCT02817308
24 To Compare the Influences of Different Methods to Remove the Pancreatic Ductal Adenocarcinoma With the Detection of Circulating Tumor Cells Unknown status NCT02451384
25 Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy Unknown status NCT02928081
26 A Clinical Validation Study on the Efficacy of MicroRNA-25 Level Detection in Assisting the Diagnosis of Pancreatic Cancer Unknown status NCT03432624
27 Continuous Monitoring of Vital Signs in Hospitalized Patients Completed NCT02933307
28 Circulating Tumor Cells Shed in Operative Blood During Pancreatectomy for Pancreatic Cancer is Responsible for Peritoneal Recurrence Completed NCT02150746
29 Impact of Nationwide Enhanced Implementation of Best Practices in Pancreatic Cancer Care (PACAP-1): a Multicenter Stepped-wedge Cluster Randomized Controlled Trial Recruiting NCT03513705
30 Mass Response of Malignant Fluid Cells as a Biomarker for Rapid Therapy Guidance Recruiting NCT05461430
31 Establishing Organoids From Metastatic Pancreatic Cancer Patients, the OPT-I Study Recruiting NCT03500068
32 A Prospective Pilot Study to Explore Performance and Efficacy of 68Ga-FAPI PET/CT in Pancreatic Ductal Carcinoma Patients Recruiting NCT05275985
33 Comprehensive Molecular Characterization of Advanced Pancreatic Ductal Adenocarcinomas (PDAC) for Better Treatment Selection: A Prospective Study Active, not recruiting NCT02750657
34 An International Multi-centre Retrospective Cohort Study Investigating Patterns of Cancer Recurrence Following Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma, Ampullary Adenocarcinoma and Distal Bile Duct Cholangiocarcinoma Active, not recruiting NCT04596865
35 A Cohort Study on Screening and Follow-up of High-risk Population of Pancreatic Cancer Based on Endoscopic Ultrasonography Not yet recruiting NCT05621824
36 Pilot Study of Personalized First-line Chemotherapy Choice for Patients With Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures (PACsign) Not yet recruiting NCT05475366
37 Predictive Factors for Resection and Survival in Type A Borderline Resectable Pancreatic Ductal Adenocarcinoma Patients After Neoadjuvant Therapy: A Retrospective Cohort Study Not yet recruiting NCT05489458
38 Role of Adrenomedullin in Early Diagnosis of Pancreatic Cancer in New Onset Diabetes Patients Terminated NCT02456051
39 A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers Terminated NCT01413451 Early Phase 1 Amatuximab (MORab-009)

Search NIH Clinical Center for Pancreatic Ductal Carcinoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


gemcitabine
Gemcitabine hydrochloride

Cochrane evidence based reviews: carcinoma, pancreatic ductal

Genetic Tests for Pancreatic Ductal Carcinoma

Anatomical Context for Pancreatic Ductal Carcinoma

Organs/tissues related to Pancreatic Ductal Carcinoma:

FMA: Pancreatic Duct
MalaCards : Pancreas, Myeloid, Liver, Lymph Node, T Cells, Lung, Prostate

Publications for Pancreatic Ductal Carcinoma

Articles related to Pancreatic Ductal Carcinoma:

(show top 50) (show all 408)
# Title Authors PMID Year
1
Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. 53 62
16951195 2006
2
Intercalated duct cell is starting point in development of pancreatic ductal carcinoma? 53 62
16018800 2005
3
Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. 53 62
15725805 2005
4
The role of chromosome 18 abnormalities in the progression of pancreatic adenocarcinoma. 53 62
15084978 2004
5
MUC1 and MUC2 expression in pancreatic ductal carcinoma obtained by fine-needle aspiration. 53 62
14681945 2003
6
Expressions of angiogenic factors in pancreatic ductal carcinoma: a correlative study with clinicopathologic parameters and patient survival. 53 62
12717266 2003
7
Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. 53 62
11787853 2001
8
Exclusion of SMAD4 mutation as an early genetic change in human pancreatic ductal tumorigenesis. 53 62
11391801 2001
9
Pancreatic intraepithelial neoplasia and infiltrating adenocarcinoma: analysis of progression and recurrence by DPC4 immunohistochemical labeling. 53 62
11431719 2001
10
Heterogeneic distribution of thymidine phosphorylase between primary tumors and metastatic lesions of human pancreatic ductal carcinoma: implications for the efficacy of chemotherapy with 5-FU or its derivatives. 53 62
11391857 2001
11
Potential significance of uncovered self-expandable metal stents for distal malignant biliary obstruction: A propensity score-adjusted competing risk regression analysis. 62
36189168 2023
12
Design, synthesis and biological evaluation of a new series of arylidene indanones as small molecules for targeted therapy of non-small cell lung carcinoma and prostate cancer. 62
36270087 2022
13
Liver Metastases: Correlation between Imaging Features and Pathomolecular Environments. 62
36149824 2022
14
Targeting KRAS in PDAC: A New Way to Cure It? 62
36291766 2022
15
Imaging of Pancreatic Ductal Adenocarcinoma: An Update on Recent Advances. 62
36065572 2022
16
Human microbiota colonization and pancreatic ductal carcinoma. 62
35924947 2022
17
Pancreatic Ductal Carcinoma Risk Associated With Hereditary Cancer-Risk Genes. 62
35445726 2022
18
Metagenomic Identification of Microbial Signatures Predicting Pancreatic Cancer From a Multinational Study. 62
35398347 2022
19
Gemcitabine Resistance in Pancreatic Ductal Carcinoma Cell Lines Stems from Reprogramming of Energy Metabolism. 62
35887170 2022
20
A multi-cellular molecular signaling and functional network map of C-C motif chemokine ligand 18 (CCL18): a chemokine with immunosuppressive and pro-tumor functions. 62
34196939 2022
21
A Small Molecule That Promotes Cellular Senescence Prevents Fibrogenesis and Tumorigenesis. 62
35743290 2022
22
Two cases of pancreatic colloid carcinoma with different pathogenesis: case report and review of the literature. 62
35048322 2022
23
Delivery of anti-cancer drugs using microbubble-assisted ultrasound in digestive oncology: from preclinical to clinical studies. 62
35363586 2022
24
Efficacy and Safety of Pancreatic Juice Cytology with Synthetic Secretin in Diagnosing Malignant Intraductal Papillary Mucinous Neoplasms of the Pancreas. 62
35328297 2022
25
The Utility of Endoscopic-Ultrasonography-Guided Tissue Acquisition for Solid Pancreatic Lesions. 62
35328306 2022
26
Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression. 62
35246474 2022
27
Sequestration of Intestinal Acidic Toxins by Cationic Resin Attenuates Pancreatic Cancer Progression through Promoting Autophagic Flux for YAP Degradation. 62
35326559 2022
28
Present status and perspective of perioperative chemotherapy for patients with resectable pancreatic cancer in Japan. 62
35291202 2022
29
Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study). 62
35123553 2022
30
The Immune Landscape of Human Pancreatic Ductal Carcinoma: Key Players, Clinical Implications, and Challenges. 62
35205742 2022
31
The Role of Nonapoptotic Programmed Cell Death - Ferroptosis, Necroptosis, and Pyroptosis - in Pancreatic Ductal Adenocarcinoma Treatment. 62
35664778 2022
32
Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation. 62
35965494 2022
33
Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer. 62
35016922 2022
34
The Obscure Potential of AHNAK2. 62
35158796 2022
35
Prophylactic vaccines against cancers of non-infectious origin: a dream or a real possibility? 62
35026062 2021
36
[A Case of Pancreatic Pseudocyst Recurrence after Surgery for Remnant Pancreatic Cancer]. 62
35046330 2021
37
AKT1/FOXP3 axis-mediated expression of CerS6 promotes p53 mutant pancreatic tumorigenesis. 62
34343636 2021
38
Metabolic syndrome related gene signature predicts the prognosis of patients with pancreatic ductal carcinoma. A novel link between metabolic dysregulation and pancreatic ductal carcinoma. 62
34930261 2021
39
Intraductal Papillary Mucinous Neoplasm of the Pancreas: Need for a Tailored Approach to a Rare Entity. 62
35851243 2021
40
Anticancer drug resistance: An update and perspective. 62
34953682 2021
41
Investigation of the utility of the 1.1B4 cell as a model human beta cell line for study of persistent enteroviral infection. 62
34341375 2021
42
DPYD, down-regulated by the potentially chemopreventive agent luteolin, interacts with STAT3 in pancreatic cancer. 62
33640964 2021
43
Ca2+ Signaling and Its Potential Targeting in Pancreatic Ductal Carcinoma. 62
34205590 2021
44
Impact of 68Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas. 62
33097632 2021
45
ACOT4 accumulation via AKT-mediated phosphorylation promotes pancreatic tumourigenesis. 62
33148467 2021
46
PDK4 dictates metabolic resistance to ferroptosis by suppressing pyruvate oxidation and fatty acid synthesis. 62
33626342 2021
47
Machine Learning of Single Cell Transcriptomic Data From anti-PD-1 Responders and Non-responders Reveals Distinct Resistance Mechanisms in Skin Cancers and PDAC. 62
35178072 2021
48
Seven Glycolysis-Related Genes Predict the Prognosis of Patients With Pancreatic Cancer. 62
33912561 2021
49
Therapeutic Approaches for Metastases from Colorectal Cancer and Pancreatic Ductal Carcinoma. 62
33466892 2021
50
Isolated Ovarian Metastasis from Pancreatic Cancer Mimicking Primary Ovarian Neoplasia: Role of Molecular Analysis in Determining Diagnosis. 62
34901699 2021

Variations for Pancreatic Ductal Carcinoma

Expression for Pancreatic Ductal Carcinoma

Search GEO for disease gene expression data for Pancreatic Ductal Carcinoma.

Pathways for Pancreatic Ductal Carcinoma

Pathways related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.68 VEGFA SMAD4 MUC6 MUC5AC MUC1 KRAS
2
Show member pathways
13.66 VEGFA TYMP SMAD4 MUC1 KRAS HRAS
3
Show member pathways
12.54 VEGFA SMAD4 KRAS HRAS CDKN2A
4
Show member pathways
12.48 CDKN2A FASLG HRAS KRAS VEGFA
5
Show member pathways
12.28 VEGFA TGM2 KRAS HRAS
6
Show member pathways
12.27 SMAD4 MUC2 MUC1 FASLG
7
Show member pathways
12.17 MUC6 MUC5AC MUC1 KRAS HRAS
8 11.63 FASLG HRAS KRAS SMAD4
9 11.6 VEGFA KRAS HRAS CHGA CDKN2A
10
Show member pathways
11.56 MUC1 MUC5AC MUC6
11 11.43 VEGFA SMAD4 FASLG
12 11.29 VEGFA KRAS HRAS
13 11.22 VEGFA SMAD4 KRAS HRAS CDKN2A
14 11.19 SMAD4 KRAS HRAS
15 11.09 VEGFA KRAS HRAS
16 11.03 SMAD4 KRAS HRAS
17 10.76 VEGFA KRAS HRAS
18
Show member pathways
10.66 KRAS HRAS
19 10.62 VEGFA TYMP KRAS HRAS CDKN2A
20 10.51 MUC6 GRP

GO Terms for Pancreatic Ductal Carcinoma

Cellular components related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix GO:0031012 9.81 VEGFA TGM2 MUC6 MUC5AC MUC2
2 Golgi lumen GO:0005796 9.5 MUC6 MUC5AC MUC2 MUC1
3 mucus layer GO:0070701 8.8 MUC5AC MUC2

Biological processes related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathway GO:1900738 8.92 GRP CHGA

Sources for Pancreatic Ductal Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....